| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -695 | -726 | -692 | -1,529 |
| Share-based compensation | 61 | 142 | 163 | 360 |
| Loss on common stock warrant liabilities | NaN | 0 | 0 | 0 |
| Change in fair value of warrant liabilities | -1 | -1 | 2 | -16 |
| Issuance of stock under founders agreement | NaN | 76 | 0 | 0 |
| License expenses paid in kind | NaN | 0 | NaN | NaN |
| Gain on repurchase of common stock held by annji | NaN | 0 | 0 | 4 |
| Receivable per license termination and transfer agreement | NaN | NaN | NaN | 800 |
| Issuance of common stock of subsidiary | NaN | 37 | NaN | NaN |
| Common stock, issued to fortress, value | 0 | 0 | 0 | 55 |
| Prepaid expenses and other current assets | -25 | 60 | -19 | -43 |
| Accounts payable and accrued expenses-Nonrelated Party | 47 | -411 | -73 | 298 |
| Accounts payable and accrued expenses-Related Party | 125 | 89 | 164 | 231 |
| Net cash used in operating activities | -438 | -854 | 383 | -1,362 |
| Proceeds from exercise of warrants | NaN | 0 | 0 | 0 |
| Proceeds from atm sales of common stock, net of issuance costs | 0 | 0 | 0 | 2,094 |
| Warrant exercise transaction costs | NaN | 0 | 0 | 0 |
| Net cash provided by financing activities | 0 | 0 | 0 | 2,094 |
| Net change in cash and cash equivalents | -438 | -854 | 383 | 732 |
| Cash and cash equivalents, beginning of period | 2,855 | 3,709 | 2,594 | NaN |
| Cash and cash equivalents, end of period | 2,417 | 2,855 | 3,709 | NaN |
AVENUE THERAPEUTICS, INC. (ATXI)
AVENUE THERAPEUTICS, INC. (ATXI)